ductal carcinoma in situ
Oncologists said the five-year outcomes data aren't enough to change standard of care but could inform conversations between patients and their doctors.
Some Recurrent Disease Following Ductal Carcinoma In Situ Unrelated to Initial Lesions, Study Finds
The finding contrasts with the previous thought that most later recurrences arise from the original ductal carcinoma in situ lesion.
The team's findings suggest that low-risk DCIS lesions may trigger an immune response that could be protective against future invasive breast cancer.
Researchers ID Genomic Signature to Risk Stratify Patients With Precancerous Breast Lesions
In the study, presented at SABCS, researchers developed an 812-gene signature that could identify which patients with ductal carcinoma in situ need aggressive treatment.
PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment
Premium
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
May 30, 2019
Sep 23, 2013
Analyst Downgrades Genomic Health to Underperform
Nov 14, 2012
May 9, 2012